These neoantigen-augmented iPSC cancer vaccines remarkably enhanced neoantigen-reactive CD8+ T cell responses and promoted the production of antitumor cytokines such as IFNγ and GzmB to eradicate tumor cells and decrease the risk of distant metastasis. This evidence concerns the gene GZMB and neoplasm.